Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.  

Dozens of colourful balloons are released into the sky at the International Rare Disease Day in Sofia, Bulgaria
Hereditary Angioedema Is a Rare Disease That Causes Extreme Swelling • Source: Alamy

The hereditary angioedema (HAE) market was shaken up last year by the launch of BioCryst Pharmaceuticals, Inc.’s plasma kallikrein inhibitor Orladeyo (berotralstat), the first oral prophylactic. Patients were previously limited to prophylactics with a more burdensome route of administration, such as Takeda Pharmaceutical Co. Ltd.’s subcutaneous plasma kallikrein inhibitor Takhzyro (lanadelumab).

HAE involves repeat episodes of swelling in the face, airway, limbs and intestines, causing vomiting, severe pain and even death...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Market Snapshot

More from Scrip